Clinical trials: Bone Mineral Density Loss
Change in Bone Mineral Density, Bone Loss
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in…
- Trial name
- NCT05303636
- Testing
- drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
- Where
- 37 sites in United States, Czechia and 1 more
- Volunteers
- 1,536 people, healthy volunteers welcome
- Sponsor
- Insud Pharma